Genprex Stock Today
| GNPX Stock | USD 1.10 0.04 3.51% |
Performance8 of 100
| Odds Of DistressOver 75
|
Genprex is trading at 1.10 as of the 25th of November 2024; that is 3.51 percent decrease since the beginning of the trading day. The stock's open price was 1.14. Genprex has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Genprex are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of February 2024 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of March 2018 | Category Healthcare | Classification Health Care |
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas. Genprex operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 8.51 M outstanding shares of which 363.38 K shares are currently shorted by private and institutional investors with about 0.02 trading days to cover. More on Genprex
Moving against Genprex Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Genprex Stock Highlights
| CEO, President | Ryan MS | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsGenprex can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Genprex's financial leverage. It provides some insight into what part of Genprex's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Genprex (GNPX) is traded on NASDAQ Exchange in USA. It is located in 3300 Bee Cave Road, Austin, TX, United States, 78746 and employs 21 people. Genprex is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.36 M. Genprex conducts business under Biotechnology sector and is part of Health Care industry. The entity has 8.51 M outstanding shares of which 363.38 K shares are currently shorted by private and institutional investors with about 0.02 trading days to cover.
Genprex currently holds about 25.52 M in cash with (24.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53.
Check Genprex Probability Of Bankruptcy
Ownership AllocationGenprex retains 6.4 (percent) of its outstanding shares held by insiders and 10.9 (percent) owned by outside corporations.
Check Genprex Ownership Details
Genprex Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Royal Bank Of Canada | 2024-06-30 | 63.0 | |
| Vitalstone Financial Llc | 2024-09-30 | 10.0 | |
| Global Retirement Partners, Llc. | 2024-09-30 | 5.0 | |
| Jpmorgan Chase & Co | 2024-06-30 | 5.0 | |
| Signaturefd, Llc | 2024-06-30 | 0.0 | |
| Brown Brothers Harriman & Co | 2024-09-30 | 0.0 | |
| Wells Fargo & Co | 2024-06-30 | 0.0 | |
| Financial Gravity Wealth, Inc. | 2024-06-30 | 0.0 | |
| Citadel Advisors Llc | 2024-06-30 | 0.0 | |
| Geode Capital Management, Llc | 2024-09-30 | 16.2 K | |
| Vanguard Group Inc | 2024-09-30 | 15.3 K |
Genprex Historical Income Statement
Genprex Stock Against Markets
Genprex Corporate Management
| CMA CPA | Co Controller | Profile | |
| Kalyn Dabbs | Sr Marketing | Profile | |
| Suzanne ThorntonJones | Senior Quality | Profile | |
| David Schloss | Senior Resources | Profile | |
| William Gannon | Member Affairs | Profile | |
| Mark MD | Chief Officer | Profile |
Additional Tools for Genprex Stock Analysis
When running Genprex's price analysis, check to measure Genprex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genprex is operating at the current time. Most of Genprex's value examination focuses on studying past and present price action to predict the probability of Genprex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genprex's price. Additionally, you may evaluate how the addition of Genprex to your portfolios can decrease your overall portfolio volatility.